drugset / Trial / NCT05886088

Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus

NCT05886088

Phase 3 Not yet recruiting 597 enrolled EMS
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of LID104 in the treatment of type 2 diabetes mellitus.

Timeline

Start
2024-02
Primary completion
2026-05
Completion
2027-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dapagliflozin Small molecule
Subject LID104 Unknown
Comparator Linagliptin Small molecule